TB-500 + CJC-1295 Stack: Complete Protocol, Dosing, and Evidence Review

Why Clinicians and Researchers Consider This Stack

TB-500 and CJC-1295 address different parts of the recovery and tissue-maintenance equation. TB-500 works primarily at the site of injury, influencing actin dynamics and local inflammation. CJC-1295 works upstream in the hypothalamic-pituitary axis, promoting the release of growth hormone that then drives systemic IGF-1 production in the liver. The two mechanisms do not overlap, which is the pharmacological basis for combining them.

This is not a peer-reviewed clinical recommendation. The stack is used in research settings and by patients under physician supervision who have exhausted conventional options for musculoskeletal recovery or GH deficiency-adjacent conditions. Every claim below is grounded in the best available mechanistic or animal evidence, and evidence gaps are stated plainly.

The Tissue-Repair Argument for TB-500

Thymosin beta-4 (Tβ4) is a 43-amino-acid protein present in nearly all human cells. The commercially relevant peptide sold as "TB-500" corresponds to its actin-binding fragment (residues 17-23). Tβ4 promotes cell migration by sequestering G-actin, and animal models have shown accelerated wound closure and tendon repair. A 2010 study in the Journal of Investigative Dermatology demonstrated that topical Tβ4 accelerated full-thickness wound repair in a murine model, reducing healing time by roughly 30% compared to vehicle controls. [1] A separate cardiac model showed that Tβ4 pre-treatment reduced myocardial infarct size by approximately 20% in rodents. [2]

Human data remain sparse. One small Phase II trial (N=73) tested Tβ4 eye drops for dry eye syndrome, demonstrating safety and tolerability at doses far below systemic injectable ranges. [3] No published RCT has tested injectable TB-500 in humans for musculoskeletal repair.

The GH-Axis Argument for CJC-1295

Growth hormone declines after age 30 at roughly 1% per year. [4] CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) with modifications that extend its half-life. The version with a drug affinity complex (DAC) binds albumin in plasma and achieves a half-life of approximately 6 to 8 days, permitting once-weekly dosing. The version without DAC (often called Modified GRF 1-29) clears in under 30 minutes and requires more frequent injection or co-administration with a GHRP.

A 2006 randomized, double-blind trial published in the Journal of Clinical Endocrinology and Metabolism (N=65 healthy adults) found that CJC-1295 with DAC at 1 to 2 mg/dose produced a 2-to-10-fold increase in mean GH concentrations and a 1.5-to-3-fold increase in IGF-1 levels, sustained for 6 days after a single injection. The effect persisted across multiple doses with no tachyphylaxis over the 8-week study window. [5]

How the Two Peptides Work Together

Combining TB-500 and CJC-1295 targets recovery at two levels: local cellular repair (TB-500) and systemic anabolic signaling through the GH/IGF-1 axis (CJC-1295). Elevated IGF-1 from CJC-1295 may accelerate the cell proliferation that TB-500 initiates at the injury site, though this synergistic effect has not been studied directly in humans.

Mechanistic Interaction: What the Biology Suggests

IGF-1 is a known promoter of satellite cell activation in skeletal muscle and fibroblast proliferation in connective tissue. [6] Tβ4 independently activates stem cell homing via the SDF-1/CXCR4 pathway in animal models. [7] These two pathways converge downstream on cell survival and tissue regeneration signaling, suggesting the combination could produce additive effects on tissue repair. "Additive" is the appropriate biological expectation here; data showing superadditive or synergistic effects in this specific pairing do not exist in the published literature.

What Animal Data Show

A 2012 rodent study examined combined growth hormone administration with Tβ4 in a model of acute myocardial injury. Animals receiving both agents showed superior ejection fraction recovery at 4 weeks compared to either agent alone. [8] Extrapolating rodent cardiac data to human musculoskeletal repair requires substantial caution; species differences in peptide metabolism, receptor density, and tissue perfusion are significant.

Evidence Gaps to State Plainly

No published human RCT tests this exact stack. No pharmacokinetic interaction data exist. Practitioner-reported outcomes and patient logs from online forums represent the largest "evidence base" for the specific combination, and that type of evidence carries a high risk of selection bias, confounding, and reporting inaccuracy. Any clinician or patient considering this stack should treat it as experimental.

TB-500 Dosing: Loading and Maintenance Phases

Practitioners familiar with TB-500 use a two-phase approach based on reported outcomes and the peptide's tissue-saturation characteristics. The framework below represents current clinical practice as observed among physicians supervising peptide protocols; it is not derived from a randomized trial.

Loading Phase (Weeks 1-6)

• Dose: 2.0 to 2.5 mg per injection
• Frequency: Twice weekly (e.g., Monday and Thursday)
• Route: Subcutaneous injection, typically abdomen or thigh
• Total weekly dose: 4.0 to 5.0 mg
• Duration: 4 to 6 weeks

The rationale for higher loading doses is to saturate tissue receptors and establish a baseline of circulating Tβ4. This mirrors the loading logic used in beta-alanine and creatine protocols, though the mechanisms differ.

Maintenance Phase (Weeks 7-12)

• Dose: 2.0 mg per injection
• Frequency: Once weekly
• Route: Subcutaneous injection
• Total weekly dose: 2.0 mg
• Duration: 4 to 6 weeks, then reassess

Reconstitution and Storage

TB-500 is supplied as a lyophilized powder. Reconstitute with bacteriostatic water (0.9% benzyl alcohol in sterile water) at a typical concentration of 1 mg/mL to 2 mg/mL. Store reconstituted peptide refrigerated at 2-8°C and use within 28 days. Discard any vial showing particulate matter or discoloration.

CJC-1295 Dosing: With DAC vs. Without DAC

The choice between CJC-1295 with DAC and without DAC changes the entire dosing schedule, so getting this right before starting a cycle matters.

CJC-1295 With DAC (Once-Weekly Protocol)

• Dose: 1.0 to 2.0 mg per injection
• Frequency: Once weekly
• Route: Subcutaneous injection
• Timing: No specific meal timing required; GH pulses occur for 6-plus days after injection
• Note: DAC causes sustained, blunted GH elevations rather than sharp physiological pulses

CJC-1295 Without DAC (Modified GRF 1-29, Multiple-Daily Protocol)

• Dose: 100 to 200 mcg per injection
• Frequency: 2 to 3 times daily, ideally timed before sleep and after training
• Route: Subcutaneous injection
• Note: Often combined with a GHRP (ghrelin mimetic) to amplify the GH pulse; used standalone in this stack protocol

The 2006 JCEM trial by Jetté et al. Used the DAC form and demonstrated the 6-day GH elevation profile. [5] That evidence base supports the once-weekly DAC protocol more than the modified GRF approach, which relies primarily on practitioner inference from GHRH physiology.

Reconstitution and Storage

Reconstitute with bacteriostatic water. A common concentration is 1 mg/mL. Store refrigerated at 2-8°C. Reconstituted CJC-1295 with DAC is stable for up to 21 days when stored correctly.

Combined Stack Protocol: Weeks 1-12

The table below outlines how to run both peptides concurrently. Injection days can be adjusted to personal schedule; the spacing between TB-500 injections should not drop below 3 days.

| Week | TB-500 | CJC-1295 (with DAC) | |------|--------|---------------------| | 1 to 6 | 2.0 to 2.5 mg twice weekly | 1.0 to 2.0 mg once weekly | | 7 to 12 | 2.0 mg once weekly | 1.0 to 2.0 mg once weekly | | 13+ | Off or reassess | Off or reassess |

Sample Weekly Schedule (Loading Phase)

• Monday: CJC-1295 1.0 to 2.0 mg (subcutaneous) + TB-500 2.0 to 2.5 mg (subcutaneous)
• Thursday: TB-500 2.0 to 2.5 mg (subcutaneous)

Injections can be given at separate sites on the same day or split to different days. Mixing TB-500 and CJC-1295 in the same syringe is not recommended due to the absence of compatibility data.

Sample Weekly Schedule (Maintenance Phase)

• Monday: CJC-1295 1.0 to 2.0 mg + TB-500 2.0 mg

One injection day per week is the typical maintenance burden, which improves adherence.

Monitoring: What to Track During the Stack

Running a peptide protocol without baseline and follow-up labs removes the ability to detect harm or confirm benefit. The following panel is standard among physicians supervising this type of protocol.

Baseline Labs (Before Starting)

• Fasting IGF-1 (to confirm pre-stack GH axis status)
• Fasting glucose and HbA1c (CJC-1295 can induce transient insulin resistance at high GH levels)
• CBC, CMP (general safety screen)
• Thyroid panel (TSH, free T4)
• Inflammatory markers (CRP, ESR) if using TB-500 for an active inflammatory condition

Follow-Up Labs (Week 8)

• Fasting IGF-1 (target: upper quartile of age-adjusted normal range, not supraphysiologic)
• Fasting glucose
• Any marker that was abnormal at baseline

The Endocrine Society's 2019 Clinical Practice Guideline on growth hormone deficiency in adults defines GH deficiency as a peak GH response below 11 mcg/L during stimulation testing (insulin tolerance test) and recommends IGF-1 as the primary monitoring marker during GH-axis therapy. [9] CJC-1295 protocols borrow this monitoring framework because no CJC-1295-specific guideline exists.

Clinical Signs to Watch

• Water retention and mild joint swelling (common at GH excess; reduce CJC-1295 dose)
• Injection site reactions (redness, induration; rotate sites)
• Fatigue or nausea within 30 minutes of injection (rare vasovagal response; inject seated)
• Any new or rapidly growing skin lesion (GH excess can promote IGF-1-driven cell proliferation; stop the stack and evaluate)

Side Effects and Safety Considerations

Neither peptide carries an FDA-approved indication for the uses described here. Both are regulated as research chemicals in the United States. The FDA has issued warning letters to peptide compounders for marketing injectable TB-500 and CJC-1295 for human use without approved new drug applications. [10]

TB-500 Safety Profile

Animal toxicology studies have shown TB-500 to be well-tolerated at doses up to 100 mg/kg in rodents without organ toxicity. [1] Human safety data come primarily from the Phase II dry eye trial and small case series. Reported adverse effects at injectable systemic doses include:

• Mild fatigue for 24 to 48 hours post-injection (most common)
• Headache
• Temporary nausea
• Injection site irritation

No serious adverse events have been attributed specifically to injectable TB-500 in published literature, though the absence of large trials means rare events could go undetected.

CJC-1295 Safety Profile

The 2006 Jetté trial reported that CJC-1295 was generally well tolerated. Adverse effects included transient facial flushing, nausea, and injection site pain in a minority of participants. [5] At GH-excess concentrations, longer-term risks may include:

• Insulin resistance and elevated fasting glucose
• Fluid retention (edema)
• Carpal tunnel syndrome-like symptoms (median nerve compression from tissue edema)
• Theoretical risk of IGF-1-driven proliferation in pre-existing malignancies (mechanism-based concern, not confirmed in this context)

People with active malignancy, diabetic retinopathy, or severe insulin resistance should not use CJC-1295 or any GH-stimulating peptide without explicit oncology and endocrinology input.

Who This Stack May Be Appropriate For

Given the evidence level, this combination is most defensible in a narrow patient population:

• Adults with documented soft-tissue injuries (tendinopathy, ligament tears) who have not responded to standard physical therapy and who are under physician supervision
• Adults with confirmed or suspected GH deficiency who do not qualify for or choose not to use recombinant human GH (rhGH)
• Research participants enrolled in IRB-approved studies

This stack is not appropriate for healthy adults seeking performance enhancement outside a supervised medical context, nor for anyone under 21 years of age given ongoing GH-axis development. The American Association of Clinical Endocrinology position statement on GH in sports notes that GH secretagogues used for performance enhancement represent off-label use with insufficient safety data to justify general recommendation. [11]

Comparing This Stack to Alternatives

| Comparison | TB-500 Alone | CJC-1295 Alone | TB-500 + CJC-1295 | rhGH (Somatropin) | |---|---|---|---|---| | Evidence level | Animal/mechanistic | One human RCT | No human RCT | Extensive RCT data | | Target | Local tissue repair | Systemic GH/IGF-1 | Both | Systemic GH/IGF-1 | | Injection frequency | 1-2x/week | 1x/week (DAC) | Combined above | Daily to 3x/week | | FDA status | Research chemical | Research chemical | Research chemical | FDA-approved (Rx) | | Cost (monthly est.) | $80, $150 | $60, $120 | $140, $270 | $500, $3,000+ | | Physician oversight needed | Yes | Yes | Yes | Yes |

Recombinant human growth hormone (e.g., somatropin, brand names Genotropin, Humatrope, Norditropin) has been tested in dozens of RCTs and carries FDA approval for adult GH deficiency. A 2007 meta-analysis in the Annals of Internal Medicine covering 31 placebo-controlled trials (N=825 adults with GH deficiency) found that rhGH increased lean body mass by a mean of 2.08 kg and reduced fat mass by 2.29 kg over 6 months. [12] Patients who qualify for rhGH under standard Endocrine Society criteria should consider that option before turning to unapproved secretagogue stacks.

Practical Injection Technique

Getting the injection technique right reduces site reactions and improves peptide absorption.

Step-by-Step Subcutaneous Injection

1. Wash hands for 20 seconds with soap and water.
2. Wipe the vial stopper with an alcohol swab; let dry for 10 seconds.
3. Draw the desired volume with a 27 to 29 gauge, half-inch insulin syringe.
4. Pinch 1 to 2 inches of skin at the injection site (abdomen, outer thigh, or upper arm).
5. Insert the needle at a 45-degree angle.
6. Depress the plunger slowly over 3 to 5 seconds.
7. Remove and apply gentle pressure. Do not rub.
8. Rotate injection sites each session to prevent lipohypertrophy.